WO2000049007A8 - Acetamido acetonitrile derivatives as inhibitors of cathepsin l and/or cathepsin s - Google Patents

Acetamido acetonitrile derivatives as inhibitors of cathepsin l and/or cathepsin s

Info

Publication number
WO2000049007A8
WO2000049007A8 PCT/GB2000/000532 GB0000532W WO0049007A8 WO 2000049007 A8 WO2000049007 A8 WO 2000049007A8 GB 0000532 W GB0000532 W GB 0000532W WO 0049007 A8 WO0049007 A8 WO 0049007A8
Authority
WO
WIPO (PCT)
Prior art keywords
cathepsin
compound
formula
medicament
acetamido
Prior art date
Application number
PCT/GB2000/000532
Other languages
French (fr)
Other versions
WO2000049007A1 (en
Inventor
Howard Tucker
Michael Stewart Large
John Oldfield
Craig Johnstone
Philip Neil Edwards
Original Assignee
Astrazeneca Ab
Howard Tucker
Michael Stewart Large
John Oldfield
Craig Johnstone
Philip Neil Edwards
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9903857.2A external-priority patent/GB9903857D0/en
Priority claimed from GBGB9916098.8A external-priority patent/GB9916098D0/en
Application filed by Astrazeneca Ab, Howard Tucker, Michael Stewart Large, John Oldfield, Craig Johnstone, Philip Neil Edwards filed Critical Astrazeneca Ab
Priority to AU25603/00A priority Critical patent/AU2560300A/en
Priority to EP00903848A priority patent/EP1155010A1/en
Priority to JP2000599747A priority patent/JP2002537293A/en
Publication of WO2000049007A1 publication Critical patent/WO2000049007A1/en
Publication of WO2000049007A8 publication Critical patent/WO2000049007A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/24—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the same saturated acyclic carbon skeleton
    • C07C255/29—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the same saturated acyclic carbon skeleton containing cyano groups and acylated amino groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/57—Nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Furan Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

A compound of formula (I) wherein Ar, R?1, R2, R3, R4 and R5¿ are defined; a composition comprising a compound of formula (I) and a carrier or diluent; a compound of formula (I) for use as a medicament, the use of a compound of formula (I) in the manufacture of a medicament for use in the inhibition of a cysteine protease in a warn blooded animal; the use of a compound of formula (I) in the manufacture of a medicament for use in the treatment of chronic obstructive pulmonary disease in a warm blooded animal; and a method of treating a Cathepsin L or Cathepsin S mediated disease state in mammals which comprises administering to a mammal in need of such treatment an effective amount of a compound of formula (I).
PCT/GB2000/000532 1999-02-20 2000-02-16 Acetamido acetonitrile derivatives as inhibitors of cathepsin l and/or cathepsin s WO2000049007A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU25603/00A AU2560300A (en) 1999-02-20 2000-02-16 Acetamido acetonitrile derivatives as inhibitors of cathepsin l and/or cathepsins
EP00903848A EP1155010A1 (en) 1999-02-20 2000-02-16 Acetamido acetonitrile derivatives as inhibitors of cathepsin l and/or cathepsin s
JP2000599747A JP2002537293A (en) 1999-02-20 2000-02-16 Acetamide acetonitrile derivatives as inhibitors of cathepsin L and / or cathepsin S

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9903857.2A GB9903857D0 (en) 1999-02-20 1999-02-20 Chemical compounds
GB9903857.2 1999-02-20
GB9916098.8 1999-07-10
GBGB9916098.8A GB9916098D0 (en) 1999-07-10 1999-07-10 Chemical compounds

Publications (2)

Publication Number Publication Date
WO2000049007A1 WO2000049007A1 (en) 2000-08-24
WO2000049007A8 true WO2000049007A8 (en) 2001-03-15

Family

ID=26315158

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2000/000532 WO2000049007A1 (en) 1999-02-20 2000-02-16 Acetamido acetonitrile derivatives as inhibitors of cathepsin l and/or cathepsin s

Country Status (4)

Country Link
EP (1) EP1155010A1 (en)
JP (1) JP2002537293A (en)
AU (1) AU2560300A (en)
WO (1) WO2000049007A1 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1452522A3 (en) * 1999-03-15 2005-02-09 Axys Pharmaceuticals, Inc. Novel compounds and compositions as protease inhibitors
KR100688740B1 (en) 1999-03-15 2007-02-28 액시스 파마슈티컬스 인코포레이티드 N-cyanomethyl amides as protease inhibitors
ATE387199T1 (en) * 2000-01-06 2008-03-15 Merck Frosst Canada Ltd NEW SUBSTANCES AND COMPOUNDS AS PROTEASE INHIBITORS
GB0003111D0 (en) 2000-02-10 2000-03-29 Novartis Ag Organic compounds
US6812237B2 (en) 2000-05-15 2004-11-02 Novartis Ag N-substituted peptidyl nitriles as cysteine cathepsin inhibitors
AU9521401A (en) * 2000-05-15 2001-11-26 Novartis Ag N-substituted peptidyl nitriles as cysteine cathepsin inhibitors
WO2002050052A1 (en) * 2000-12-20 2002-06-27 Syngenta Participations Ag N-acyl aminoacetonitriles having pesticidal properties
US7030116B2 (en) 2000-12-22 2006-04-18 Aventis Pharmaceuticals Inc. Compounds and compositions as cathepsin inhibitors
JP2004523506A (en) 2000-12-22 2004-08-05 アクシス・ファーマシューティカルズ・インコーポレイテッド Novel compounds and compositions as cathepsin inhibitors
CA2439415C (en) 2001-03-02 2011-09-20 Merck Frosst Canada & Co. Cathepsin cysteine protease inhibitors
US6982263B2 (en) * 2001-06-08 2006-01-03 Boehringer Ingelheim Pharmaceuticals, Inc. Nitriles useful as reversible inhibitors of cysteine proteases
EP1436255A1 (en) 2001-09-14 2004-07-14 Aventis Pharmaceuticals, Inc. Novel compounds and compositions as cathepsin inhibitors
KR20050044497A (en) 2001-11-14 2005-05-12 아벤티스 파마슈티칼스 인크. Oligopeptides and compositions containing them as cathepsin s inhibitors
WO2003075836A2 (en) 2002-03-05 2003-09-18 Merck Frosst Canada & Co. Cathepsin cysteine protease inhibitors
US6878706B1 (en) 2002-04-05 2005-04-12 Boehringer Ingelheim Pharmaceuticals Inc. Cyanamides useful as reversible inhibitors of cysteine proteases
AU2003230772A1 (en) * 2002-04-05 2003-10-27 Boehringer Ingelheim Pharmaceuticals, Inc. Cyanamides useful as reversible inhibitors of cysteine proteases
KR100962972B1 (en) 2002-07-26 2010-06-09 주식회사유한양행 1-phenylpiperidin-3-one derivatives and processes for the preparation thereof
JP4505329B2 (en) 2002-09-04 2010-07-21 メルク フロスト カナダ リミテツド Cathepsin cysteine protease inhibitor
PL408347A1 (en) 2002-09-24 2014-08-18 Novartis Ag Combination use of a combination and the use of S1P receptor agonist
US7326719B2 (en) 2003-03-13 2008-02-05 Boehringer Ingelheim Pharmaceuticals, Inc. Cathepsin S inhibitors
US7465745B2 (en) 2003-03-13 2008-12-16 Boehringer Ingelheim Pharmaceuticals, Inc. Cathepsin S inhibitors
WO2004089395A2 (en) * 2003-04-01 2004-10-21 Aventis Pharmaceuticals Inc. Use of an inhibitor of cathepsin-s or -b to treat or prevent chronic obstructive pulmonary disease
US7297714B2 (en) * 2003-10-21 2007-11-20 Irm Llc Inhibitors of cathepsin S
US7423176B2 (en) * 2004-04-13 2008-09-09 Cephalon, Inc. Bicyclic aromatic sulfinyl derivatives
US7737300B2 (en) * 2004-09-17 2010-06-15 Virobay, Inc. Processes and intermediates preparing cysteine protease inhibitors
WO2006128287A1 (en) * 2005-06-02 2006-12-07 Merck Frosst Canada Ltd. Fluoroalkylamine derivatives as cathepsin inhibitors
AU2006278867A1 (en) * 2005-07-25 2007-02-15 Novartis Ag Amidonitrile compounds
JP5587790B2 (en) 2008-01-09 2014-09-10 アミュラ セラピューティクス リミティド Compound
WO2009155475A1 (en) 2008-06-20 2009-12-23 Novartis Ag Paediatric compositions for treating1 multiple sclerosis
EP2198879A1 (en) 2008-12-11 2010-06-23 Institut Curie CD74 modulator agent for regulating dendritic cell migration and device for studying the motility capacity of a cell
CA2889042A1 (en) * 2012-11-14 2014-05-22 F. Hoffmann-La Roche Ag Novel acetamide derivatives as trp channel antagonists
AU2014319290B2 (en) 2013-09-13 2019-07-18 Pitney Pharmaceuticals Pty Limited Anticancer agent comprising aminoacetonitrile compound as active ingredient
CN115466225A (en) * 2022-08-16 2022-12-13 中国科学院上海药物研究所 Amide compound, preparation method, pharmaceutical composition and application thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2846127A1 (en) * 1978-10-23 1980-04-30 Basf Ag 1,2,4-TRIAZOL-1-YL COMPOUNDS, THEIR PRODUCTION AND USE AS FUNGICIDES
FR2446812A1 (en) * 1979-01-16 1980-08-14 Produits Ind Cie Fse PHENOXY- AND THIOPHENOXYNITRILES AND THEIR APPLICATIONS AS HERBICIDES
US4567267A (en) * 1981-06-15 1986-01-28 American Home Products Corporation α-Phenyl-2-(aza)benzothiazolylthioglycolic acids and derivatives thereof
EP0262393B1 (en) * 1986-08-29 1993-01-07 Shell Internationale Researchmaatschappij B.V. Derivatives of aryloxycarbonic acids, their preparation and their use
US5055451A (en) * 1986-12-22 1991-10-08 Syntex Inc. Aryloxy and arylacyloxy methyl ketones as thiol protease inhibitors
JPH03218347A (en) * 1989-11-10 1991-09-25 Nippon Soda Co Ltd Carboxylic acid amide derivative and its preparation
JPH05286937A (en) * 1992-04-10 1993-11-02 Mitsubishi Petrochem Co Ltd Substituted pyridyloxycarboxylic acid amide derivative and agricultural bactericide containing the same
JPH06211766A (en) * 1993-01-18 1994-08-02 Mitsubishi Petrochem Co Ltd Alkoxycarboxylic acid amide derivative and agricultural fungicide containing the derivative
JP2848232B2 (en) * 1993-02-19 1999-01-20 武田薬品工業株式会社 Aldehyde derivatives
US5486623A (en) * 1993-12-08 1996-01-23 Prototek, Inc. Cysteine protease inhibitors containing heterocyclic leaving groups
KR100511339B1 (en) * 1996-10-31 2005-08-31 구미아이 가가쿠 고교 가부시키가이샤 Pyrimidinyloxyalkanoic amide derivatives and fungicides for agricultural and horticultural use
US5942640A (en) * 1998-04-20 1999-08-24 American Cyanamid Company Process for the manufacture of N-(1-cyanoalkyl)-2-phenoxypropionamide derivatives

Also Published As

Publication number Publication date
AU2560300A (en) 2000-09-04
EP1155010A1 (en) 2001-11-21
JP2002537293A (en) 2002-11-05
WO2000049007A1 (en) 2000-08-24

Similar Documents

Publication Publication Date Title
WO2000049007A8 (en) Acetamido acetonitrile derivatives as inhibitors of cathepsin l and/or cathepsin s
WO2000058293A3 (en) Glucokinase activators
WO2001066564A3 (en) Gamma-secretase inhibitors
MXPA04001500A (en) Compounds effecting glucokinase.
DE60114994D1 (en) PLATELET ADP RECEPTOR INHIBITORS
BR0212042A (en) Compound, pharmaceutical composition, method of treating or preventing disease, and use of a compound
WO2005063745A3 (en) Novel spiroindoline or spiroisoquinoline compounds, methods of use and compositions thereof
WO2004022523A3 (en) 1, 3-diamino-2-hydroxypropane prodrug derivatives
WO2003044015A3 (en) Substituted heteroarylalkanoic acids and their use as aldose reductase inhibitors
WO2004094384A3 (en) (hetero) arylamide 2-hydroxy-3-diaminoalkanes for use in the treatment of alzheimer’s disease
WO2002085909A8 (en) 9-deazaguanine derivatives as inhibitors of gsk-3
WO2005007681A3 (en) Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
WO2001081312A3 (en) Method of treatment using phenyl and biaryl derivatives as prostaglandin e inhibitors and compounds useful therefore
WO2001072728A3 (en) Novel piperazine derivatives
CA2427227A1 (en) Lactam compound
AU2003284632A1 (en) Isoquinoline compounds and medicinal use thereof
EP2039687A4 (en) Therapeutic or prophylactic agent for multiple sclerosis
WO2003029169A3 (en) Hydroxypropylamines
CA2283399A1 (en) Pyridazinones as inhibitors of cyclooxygenase-2
CA2301742A1 (en) 2,3,5-trisubstituted pyridines as inhibitors of cyclooxygenase-2
GEP20074045B (en) (4-phenyl) piperidin-3-yl-phenylcarboxylate derivatives and related compounds as beta-secretase inhibitors for the treatment of alzheimer's disease
WO2002102787A3 (en) Novel sulfonic acid derivatives
WO2003049690A3 (en) Hiv integrase inhibitors
WO2003053971A8 (en) Pyridoquinoxaline antivirals
WO2003006443A3 (en) 2- 4-(naphtalin-2-yl)-thiazol-2-ylaminocarbonyl benzoic acid and 2- 4-(naphtalin-2-yl)-pyrimidin-2-ylaminocarbonyl benzoic acid and additional compounds serving as telomerase inhibitors for use in tumor therapy

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: C1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: PAT. BUL. 34/2000 UNDER (51) AFTER "C07D277:00" INSERT "C07D235:00"

WWE Wipo information: entry into national phase

Ref document number: 2000903848

Country of ref document: EP

ENP Entry into the national phase in:

Ref country code: JP

Ref document number: 2000 599747

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 09913769

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2000903848

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000903848

Country of ref document: EP

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)